Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer of multiple types in stage II, III, or IV and not a candidate for chemotherapy; but may have been receiving radiation therapy~* Fair, poor, or very poor appetite~* Cancer-associated anorexia/cachexia (documented weight loss of 2% over the prior week, or at least 5% within past 30 days, or at least 7.5% over prior 3 months, or at least 10% over prior 6 months)~* Weight loss perceived to be associated with diminished appetite~* Eastern Cooperative Oncology Group Performance score of 0, 1, or 2~* Life expectancy greater than 3 months~* Alert and mentally competent to complete study assessments~* Women of child-bearing potential required to use an adequate and reliable method of contraception. Post-menopausal women have to have been so for at least 1 year~* Screening laboratory values must not be clinically significant (some exceptions per protocol)~Exclusion Criteria:~* Brain, or head and neck tumors that may interfere with food consumption~* AIDS-related wasting~* Radiation therapy to head and neck, abdomen, or pelvis within past 6 weeks, or for whom radiation therapy is anticipated during the study such that the result may interfere with food consumption~* Presence of conditions that interfere with oral intake or ability to swallow~* Absence of normally functioning gut~* Known mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome~* Intractable or frequent vomiting~* Clinically significant diarrhea~* History of thromboembolic events, or on long-term anticoagulation for thromboembolism~* Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism~* Poorly controlled hypertension or congestive heart failure~* Pregnant/lactating females, or planning on becoming pregnant~* Use of appetite stimulants within past 30 days~* Use of parenteral nutrition or tube feedings within past 1 week~* Chronic use of steroids within past 3 months (intermittent short-term use allowed)~* Current use of illicit substances~* Allergy, hypersensitivity, or other contraindication to megestrol acetate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Megestrol acetate concentrated suspension 110 mg/mL
- 2 (Type: ACTIVE_COMPARATOR): Megestrol acetate concentrated suspension 60 mg/mL
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).